The prognostic value of tumor budding in a thoroughly characterized stage II colon cancer population in the context of a national screening program.

Directed acyclic graph Screening Survival Tumor budding UICC stage II colon cancer

Journal

Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547

Informations de publication

Date de publication:
28 Feb 2024
Historique:
received: 22 12 2023
revised: 20 02 2024
accepted: 26 02 2024
medline: 2 3 2024
pubmed: 2 3 2024
entrez: 1 3 2024
Statut: aheadofprint

Résumé

Tumor budding as a prognostic marker in colorectal cancer has not previously been investigated in a cohort of screened stage II colon cancer patients. We assess the prognostic significance of tumor budding in a thoroughly characterized stage II colon cancer population comprising surgically resected patients in the Region of Southern Denmark from 2014 to 2016. Tumors were re-staged according to the 8th edition of UICC TNM Classification, undergoing detailed histopathological evaluation and tumor budding assessment following guidelines from the International Tumor Budding Consensus Conference. Prognostic evaluation utilized Kaplan-Meier curves, log-rank tests, and Cox proportional hazard models for time to recurrence (TTR), recurrence-free survival (RFS), and overall survival (OS). Out of 497 patients, 20% were diagnosed through the national colorectal cancer screening program. High-grade tumor budding (Bd3) was found in 19%, and tumor budding was associated with glandular subtype, perineural invasion, mismatch repair proficient tumors, and tumor recurrence (p < 0.001, p < 0.001, p = 0.045 and p = 0.007 respectively). In multivariable Cox regression, high-grade tumor budding (Bd3) was a significant prognostic factor for TTR compared to low-grade (Bd3 HR 2.617; p = 0.007). An association between tumor budding groups and RFS was observed, and the difference was significant in univariable analysis for high-grade compared to low-grade tumor budding (Bd3 HR 1.461; p = 0.041). No significant differences were observed between tumor budding groups and OS. High-grade tumor budding is a predictor of recurrence in a screened population of patients with stage II colon cancer and should be considered a high-risk factor in a shared decision-making process when stratifying patients to adjuvant chemotherapy.

Identifiants

pubmed: 38428823
pii: S0046-8177(24)00033-9
doi: 10.1016/j.humpath.2024.02.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest None

Auteurs

Maria Pihlmann Kristensen (M)

Department of Pathology, Vejle Hospital, University Hospital of Southern Denmark, 7100, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, 5000, Odense, Denmark; Colorectal Cancer Center South, 7100, Vejle, Denmark. Electronic address: maria.pihlmann.kristensen@rsyd.dk.

Ulrik Korsgaard (U)

Department of Pathology, Vejle Hospital, University Hospital of Southern Denmark, 7100, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, 5000, Odense, Denmark; Colorectal Cancer Center South, 7100, Vejle, Denmark.

Signe Timm (S)

Institute of Regional Health Research, University of Southern Denmark, 5000, Odense, Denmark; Colorectal Cancer Center South, 7100, Vejle, Denmark; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, 7100, Vejle, Denmark.

Torben Frøstrup Hansen (TF)

Institute of Regional Health Research, University of Southern Denmark, 5000, Odense, Denmark; Colorectal Cancer Center South, 7100, Vejle, Denmark; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, 7100, Vejle, Denmark.

Inti Zlobec (I)

Institute of Tissue Medicine and Pathology, University of Bern, 3008, Bern, Switzerland.

Henrik Hager (H)

Department of Pathology, Vejle Hospital, University Hospital of Southern Denmark, 7100, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, 5000, Odense, Denmark; Colorectal Cancer Center South, 7100, Vejle, Denmark; Department of Pathology, Aarhus University Hospital, 8200, Aarhus N, Denmark.

Sanne Kjær-Frifeldt (S)

Department of Pathology, Vejle Hospital, University Hospital of Southern Denmark, 7100, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, 5000, Odense, Denmark; Colorectal Cancer Center South, 7100, Vejle, Denmark.

Classifications MeSH